Lv1
20 积分 2025-05-06 加入
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
4天前
已完结
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
10天前
已完结
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
11天前
已完结
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma
1个月前
已完结
Global, Regional, and National Burden of Breast Cancer Among Females, 1990–2023, With Forecasts to 2050: A Systematic Analysis for the Global Burden of Disease Study 2023
1个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
4个月前
已完结
皖公网安备34019202002308
